Correction: Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model

Correction: Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model

Saved in:

Bibliographic Details
Main Authors:	Douglas M. Lopes, Jack A. Wells, Da Ma, Lauren Wallis, Daniel Park, Sophie K. Llewellyn, Zeshan Ahmed, Mark F. Lythgoe, Ian F. Harrison
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Series:	Alzheimer’s Research & Therapy
Online Access:	https://doi.org/10.1186/s13195-024-01624-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model
by: Douglas M. Lopes, et al.
Published: (2024-04-01)

Glymphatic system clearance and Alzheimer’s disease risk: a CSF proteome-wide study
by: Natalia Cullell, et al.
Published: (2025-01-01)

The role and mechanism of Aβ clearance dysfunction in the glymphatic system in Alzheimer’s disease comorbidity
by: Hailang Li, et al.
Published: (2024-11-01)

Diffusion Tensor Imaging Analysis Along the Perivascular Space (DTI-ALPS) Demonstrates That Sleep Disorders Exacerbate Glymphatic Circulatory Impairment and Cognitive Impairment in Patients with Alzheimer’s Disease
by: Shang Y, et al.
Published: (2024-12-01)

New perspectives on the glymphatic system and the relationship between glymphatic system and neurodegenerative diseases
by: Yan-rui Sun, et al.
Published: (2025-02-01)

Epigenetic Modulation on Tau Phosphorylation in Alzheimer’s Disease
by: Chao-Chao Yu, et al.
Published: (2019-01-01)

pTau pathology in the retina of TAU58 mice: association with ganglion cell degeneration and implications on seeding and propagation of pTau from human brain lysates
by: Grzegorz Walkiewicz, et al.
Published: (2024-12-01)

Enhancing glymphatic fluid transport by pan-adrenergic inhibition suppresses epileptogenesis in male mice
by: Qian Sun, et al.
Published: (2024-11-01)

Electroacupuncture Improves Clearance of Amyloid-β through the Glymphatic System in the SAMP8 Mouse Model of Alzheimer’s Disease
by: Pei-zhe Liang, et al.
Published: (2021-01-01)

Modulation of glymphatic system by visual circuit activation alleviates memory impairment and apathy in a mouse model of Alzheimer’s disease
by: Wen Wu, et al.
Published: (2025-01-01)

Functional abnormalities of the glymphatic system in cognitive disorders
by: Wuyue Shentu, et al.
Published: (2025-12-01)

The structure, functions and clinical significance of the glymphatic system
by: Tansu Kuşat, et al.
Published: (2021-12-01)

Progress in magnetic resonance imaging of the glymphatic system
by: Jinhao Lyu, et al.
Published: (2024-11-01)

Circuitry and Synaptic Dysfunction in Alzheimer’s Disease: A New Tau Hypothesis
by: Siddhartha Mondragón-Rodríguez, et al.
Published: (2020-01-01)

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
by: Futao Zhou, et al.
Published: (2024-10-01)

Tau-network mapping of domain-specific cognitive impairment in Alzheimer’s disease
by: Ying Luan, et al.
Published: (2024-01-01)

Hippocampal tau‐induced GRIN3A deficiency in Alzheimer's disease
by: Sang‐Eun Lee, et al.
Published: (2024-12-01)

Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis
by: Jinwang Ye, et al.
Published: (2025-01-01)

Glymphatic system: a self-purification circulation in brain
by: Siying Chen, et al.
Published: (2025-02-01)

Glymphatic system in neurological disorders and implications for brain health
by: Osman Corbali, et al.
Published: (2025-02-01)

Comprehensive review on Alzheimer's disease: From the posttranslational modifications of Tau to corresponding treatments
by: Xin Li, et al.
Published: (2024-12-01)

Tau mediates the reshaping of the transcriptional landscape toward intermediate Alzheimer’s disease stages
by: Giacomo Siano, et al.
Published: (2025-01-01)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
by: Hossein Moein Taghavi, et al.
Published: (2024-10-01)

Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer’s Disease
by: Lenka Hromadkova, et al.
Published: (2019-01-01)

Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
by: Jon B. Toledo, et al.
Published: (2022-01-01)

The glymphatic system: A new insight into the understanding of neurological diseases
by: Junbo Liao, et al.
Published: (2024-12-01)

Surgery impairs glymphatic activity and cognitive function in aged mice
by: Kai Chen, et al.
Published: (2025-01-01)

Evolutionary changes leading to efficient glymphatic circulation in the mammalian brain
by: Narufumi Kameya, et al.
Published: (2024-12-01)

Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers
by: Anna L. Wojdała, et al.
Published: (2025-01-01)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
by: Yury Loika, et al.
Published: (2024-10-01)

Self‐Aggregating Tau Fragments Recapitulate Pathologic Phenotypes and Neurotoxicity of Alzheimer's Disease in Mice
by: Ly Thi Huong Luu Le, et al.
Published: (2023-10-01)

Hyperphosphorylated tau targeting human serum albumin Fusion protein as therapeutics for Alzheimer’s diseases
by: Sookhee Bang, et al.
Published: (2024-12-01)

Abnormal glymphatic system in patients with autoimmune encephalitis: Relationship with cognitive performance
by: Yingchi Zhang, et al.
Published: (2025-02-01)

Genome-wide association study unravels mechanisms of brain glymphatic activity
by: Shu-Yi Huang, et al.
Published: (2025-01-01)

Traditional Chinese medicine in Alzheimer's disease: From the perspective of GSK-3β and Tau hyperphosphorylation
by: Mei Wang, et al.
Published: (2024-12-01)

Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers
by: Eun Woo Kim, et al.
Published: (2025-02-01)

Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology
by: Alessandro Padovani, et al.
Published: (2025-01-01)

Predicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics
by: Saima Rathore, et al.
Published: (2024-10-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024-10-01)